Michaela Dinboeck is Senior Director of Group Patient Advocacy and Communications in Novartis International. She has over 20-years of experience in the Pharmaceutical Industry in commercial positions at local, regional and global level. Prior to joining Patient Advocacy, she was the President and Managing Director for Novartis Malaysia and Brunei. During her tenure in Malaysia, was on the BOD of the Pharmaceutical Association, in the CEO Faculty of the Ministry of Education and Adjunct Professor in the National University. Previous experience includes Top 5 market and regional Franchise Head roles as well as General Management of a world wide operating start-up for implantable Medical Devices. She combines the experience in various disease areas from established- and in emerging markets where she always put a strong focus on programs for access to medicines and capability building.
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Drive Patient Centricity & Engagement With Meaningful Patient Involvement
Senior Director Group Patient Advocacy & Communications
I will relentlessly work to ensure that associates across divisions, functions and countries embrace the role they play in embedding the patient perspective in our daily workWork in progress